Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989，NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 1025 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MmDlR5l1d3SxeHnjJGF{e2G7 NFvKTJkyOCCwTR?= MX63NkBp M1vJPWROW09? MWjQc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm= NH7hUoczPDlyMEi3Ny=>
HT-29 MV7DfZRwfG:6aXOgRZN{[Xl? NH\0fW4yOCCwTR?= Ml3xO|IhcA>? MULEUXNQ NWHCXY85WG:2ZX70bYF1\XNiZHnnbZRwgGmwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 M4SxcFI1QTByOEez
HT-29 MojUR5l1d3SxeHnjJGF{e2G7 NITTWJAyOCCwTR?= Mn;uO|IhcA>? M4fkTmROW09? NEL2U4NRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? MWKyOFkxODh5Mx?=
PC3 NWTEPXliU2mwYYPlJGF{e2G7 MXSxNFAhdk1? NWTBPXdzOSCq M2SxXmROW09? NVHwcphFWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDxzMDDuUU4> MYeyNVk4QDZ6Mx?=
PC3 MVvLbY5ie2ViQYPzZZk> M3nKUlExOCCwTR?= M2TYWVEhcA>? MVXEUXNQ M12xNmRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w NEfNWpEzOTl5OE[4Ny=>
PC3 M1TjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYexMlUh|ryP NIfhclQyKGh? NGe3bnhFVVOR M4HBN2lv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFwyOCCwTR?= NIDRNHkzOTl5OE[4Ny=>
HEK293 NH\6NVVHfW6ldHnvckBCe3OjeR?= MmfMNVAxKG6P NXfBWIFPQCCq MVLEUXNQ M{CzbGlvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?= NHrSOVEzOTV|OUOwNS=>
BT-20 NIP6WmJMcW6jc3WgRZN{[Xl? MXqyNEDPxE1? NX3IR5FUTE2VTx?= NUDB[FA4TG:nczDuc5QhcW6qaXLpeEBuXE:UQ{Kg[IVx\W6mZX70JJBCc1RiU{S3N{BxcG:|cHjvdplt[XSrb36= Moe1NlE{PTN3NUG=
U937 M{[wSGFvfGmkYXP0[ZJq[WxiQYPzZZk> Ml7sOVAh|ryP MVq0PEBp M4PzVmROW09? NIfJeGJKdmS3Y3XzJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCC5aXzkJJR6eGViTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBRcGmuYXTlcJBpcWFvMTDKVlMzKGmwIGW5N|ch[2WubIO= NWn4fpVbOjFzNEKxNFY>
U937 NYHJToJKSW62aXLhZ5RmemmjbDDBd5NigQ>? NYriPXJXPTBizszN MV:0PEBp NEjoVXBFVVOR Mn3sSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? MoG0NlEyPDJzME[=
U937 NFjhZplCdnSrYnHjeIVzcWGuIFHzd4F6 NEXKbYg2OCEQvF2= NET4UlE1QCCq NX7uS4xzTE2VTx?= NWraVIpSTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCHc3Po[ZJq[2irYTDjc4xqKEiEMUCxJIlvKFV7M{egZ4VtdHN? NUnnW4V6OjFzNEKxNFY>
MCF-7 M1zPOmF2fG:yaHHnfUBCe3OjeR?= NXz1V49rOzBibl2= Mn7oOEBp NXfC[GhrTE2VTx?= M2XiXWlv\HWlZYOgZZV1d3CqYXf5 MYqyNFAzQDF|NB?=
U87MG M4Lvb2tqdmG|ZTDBd5NigQ>? NVPw[o5tOSEQvF2= NXLQelRMPiCq NHS4OotFVVOR MUXQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>? MmDYNVk5PDh2MES=
U87MG MX;LbY5ie2ViQYPzZZk> NVjGTGdHOSEQvF2= M4fvd|YhcA>? MkG0SG1UVw>? MYHQc5RmdnSueTDpcohq[mm2czC0SWJROSiWN{CpJJBpd3OyaH;yfYxifGmxbh?= NF3URnoyQTh2OESwOC=>
U87MG Mnj4T4lv[XOnIFHzd4F6 NV;OU4prOSEQvF2= M322cVYhcA>? NIXnb5NFVVOR M2XqemRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w NGfEfXEyQTh2OESwOC=>
U87MG MXLLbY5ie2ViQYPzZZk> NYL1[JVnOSEQvF2= MVG2JIg> NFnYU3FFVVOR MV;Ec4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44> NGP5dIUyQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb MlyxRZV1d3CqYXf5JGF{e2G7 M4rGfFAvOiEQvF2= NYDDWotiOjRiaB?= Mli5SG1UVw>? MXfJcoR2[2W|IHH1eI9xcGGpeR?= NYTFfphDOTh|OUG5OFk>
COS7 cells expressing EGFP-LC3 NG\LcmVCfXSxcHjh[5khSXO|YYm= MVWwMlIh|ryP MWSyOEBp NELJSG5FVVOR NVzD[5RLUW6mdXPld{BifXSxcHjh[5k> NFfrSIsyQDN7MUm0PS=>
H4 NXe4e3RRTnWwY4Tpc44hSXO|YYm= M2rPZVAvOiEQvF2= NEDUNWczPCCq NXLIZ4Q2TE2VTx?= NWPkd4ZzUW6lcnXhd4V{KHSqZTDyZZRqdyCxZjDsbYdpfCClaHHpckA{KHO3YoXubZQhOiC2bzDsbYdpfCClaHHpckA{KHO3YoXubZQhOSCrbjDoeY1idiCKNDDj[Yxtew>? NVyzbId4OThyMkS1PFQ>
HeLa MWXGeY5kfGmxbjDBd5NigQ>? MoLsNVAxKG6P MUSzOkBp M1rWVWROW09? MkD5TY5lfWOnczDGVmIhUzJyOUXQMEBVOjB7OFysJHczOTBzRjDteZRidnRvdXLpdZVqfGmwQzDpcpRmemGldHnvci=> MXOxO|U3OzN6NR?=
HeLa NH;XbplHfW6ldHnvckBCe3OjeR?= Mlf3NVAxKG6P NWflSW1HOzZiaB?= NXrzSZZvTE2VTx?= M4nvc2lv\HWlZYOgSnJDKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? NV7oNGt2OTd3NkOzPFU>
HeLa NFjySlRHfW6ldHnvckBCe3OjeR?= NGeyfI4yODBibl2= MmLyN|YhcA>? NFjNfllFVVOR NF7L[ZZKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NIL0bYkyPzV4M{O4OS=>
SYF M1\IOWZ2dmO2aX;uJGF{e2G7 MV6xNFAhdk1? MXqyOEBp MVrEUXNQ MnvkTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u M{HVOFE4PTZ|M{i1
SYF MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;4VZBEOTByIH7N MVeyOEBp MkTFSG1UVw>? Mn3HTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGPZSkBk\Wyucx?= M4HUUFE4PTZ|M{i1
HEK293T M3LBWmFvfGm4aYLhcEBCe3OjeR?= MVexJI5O Mn;JOEBl NFjPb3hFVVOR MorMTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFJ3IIfpeIghTUN3MDDv[kAxNjFibl2= NE\sUVMyPzR6NUWwNS=>
HEK293T MlLiRY51cX[rcnHsJGF{e2G7 NYXDWnV2OSCwTR?= NYrRUnFlPCCm MkPFSG1UVw>? M4LwcGlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC[NDD3bZRpKEWFNUCgc4YhOC5|IH7N M{nZTVE4PDh3NUCx
PBMC M1j4UWZ2dmO2aX;uJGF{e2G7 NV;GSHB7OSCwTR?= NH;kS2UyPCCm M1;JXGROW09? M4DXWXJm\HWlZYOgR2NTPSCmZX7zbZR6 MYWxO|Q5PTVyMR?=
PBMC NYnTe3dUTnWwY4Tpc44hSXO|YYm= NXK4PWo3OSCwTR?= NILMTY0yPCCm M4DBS2ROW09? MXjEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=> NHvvc28yPzR6NUWwNS=>
HEK293 cells MYTLbY5ie2ViQYPzZZk> NETkOZk2OCCwTR?= NWHoSWlXPDVibXnu Ml\JSG1UVw>? NVT6TohZUW6qaXLpeJMhdVSRUjDrbY5ie2ViYXP0bZZqfHlid3n0bEBKSzVyIH;mJFAvOSCwTR?= NYD4NmJMOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MnXESpVv[3Srb36gRZN{[Xl? M2PGNFExOCCwTR?= M4[1XVQhcA>? Mof0SG1UVw>? NVfqOppwUW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN? MknrNVcyOjh{NkK=
Human mixed lymphocyte M3y4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\YOIU2KG6P MX7EUXNQ NH7LbohKSzVyPUGuOkBvVS5? NVXLfnMzOTZzOEW4OlU>
Lewis rat lymph node cells NIO1RXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\vOUDPxE1? MYfEUXNQ MkTuTWM2OD1{Lk[g{txO MnLTNVYyQDV6NkW=
cells from the thymus of normal BALB/c mice NEfJOm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\JVFExKG6P MVS3NkBp NXP3ZphHTE2VTx?= MXLJcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P MUixNFAzOTl2OB?=
MRK-nu-1 Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:2eYdKSzVyPUCuPFQ2KHCP M{XWTHNCVkeHUh?=
OCUB-M NEf0Zm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTVwMkSgdG0> Mly0V2FPT0WU
SF539 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jUWGlEPTB;MUGuOkBxVQ>? MVPTRW5ITVJ?
ES4 MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zDXWlEPTB;MkGuOUBxVQ>? MmLQV2FPT0WU
RL95-2 NFvwXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfuTWM2OD1zMEegdG0> NHLLPGpUSU6JRWK=
LC-2-ad NI[zVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTR{MzDwUS=> NHzaUnBUSU6JRWK=
Daudi NFi2XGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPzTWM2OD12M{SgdG0> NX3mTFY5W0GQR1XS
NTERA-S-cl-D1 M3nFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;yUWlEPTB;NESzJJBO MkLlV2FPT0WU
OS-RC-2 MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX4OVNKSzVyPU[1NkBxVQ>? NUnOV21OW0GQR1XS
VA-ES-BJ MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\4bGlEPTB;N{KzJJBO NIPUUHRUSU6JRWK=
GR-ST M{Plc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTr[odtUUN3ME24OFYheE1? MUjTRW5ITVJ?
SW872 M1[3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTh2NjDwUS=> NF\vSWhUSU6JRWK=
NOS-1 M3\ybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHqcY0zUUN3ME24O|EheE1? NVzIXY55W0GQR1XS
MC116 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXkTWM2OD17OEWgdG0> MUHTRW5ITVJ?
NCI-H1355 NFvlNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrrRVZKSzVyPUGuNFEhdk1? NVTNPZdbW0GQR1XS
RPMI-8226 NVjRbYFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnKTWM2OD1zLkG5JI5O M1TiOnNCVkeHUh?=
TE-15 NXTnXnBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTqRoFpUUN3ME2xMlM3KG6P NEHldm9USU6JRWK=
Ramos-2G6-4C10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwNE[gcm0> NHrnWXlUSU6JRWK=
KU812 M33rVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3oeZlXUUN3ME2yMlAyKG6P MX3TRW5ITVJ?
EW-1 NIW1V3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXn5OFR2UUN3ME2yMlE4KG6P MUPTRW5ITVJ?
KS-1 MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLmTWM2OD1{LkS1JI5O MV7TRW5ITVJ?
SK-LMS-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPBTWM2OD1{LkS5JI5O MlPkV2FPT0WU
TGBC1TKB MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PSWWlEPTB;Mj62PUBvVQ>? NHvWepNUSU6JRWK=
TE-6 NH;hZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITqXnFKSzVyPUKuO|chdk1? NW\1dnFLW0GQR1XS
ETK-1 MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTDNlhOUUN3ME2yMlgzKG6P MU\TRW5ITVJ?
BE-13 MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwOUmgcm0> MkjNV2FPT0WU
A3-KAW M1zvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfjcXFKSzVyPUKuPVkhdk1? NEDRPZRUSU6JRWK=
TE-10 MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnacHBOUUN3ME2zMlMhdk1? M3vNOHNCVkeHUh?=
DOHH-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTkRm03UUN3ME2zMlM2KG6P NUDZbYlvW0GQR1XS
ES6 NVznXoZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4KxVGlEPTB;Mz60N{BvVQ>? Mo\aV2FPT0WU
OPM-2 MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTRwMUWgcm0> MYTTRW5ITVJ?
SH-4 M1zNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PyOWlEPTB;ND6zOEBvVQ>? M{T2Z3NCVkeHUh?=
NB13 NUPZeZZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTRwM{[gcm0> NVm0VWk2W0GQR1XS
HUTU-80 MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u5PGlEPTB;ND60NkBvVQ>? NEXnc5NUSU6JRWK=
CCRF-CEM MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvBTWM2OD12Lkm0JI5O MlLpV2FPT0WU
TGBC24TKB M1Lh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjsZW5yUUN3ME21MlUyKG6P Mo\JV2FPT0WU
697 NYS3d|llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\0OZJKSzVyPU[uNlghdk1? NViwWnlIW0GQR1XS
J-RT3-T3-5 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3qy[2lEPTB;Nj60OkBvVQ>? NHv3[WhUSU6JRWK=
KALS-1 MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;hTIxKSzVyPU[uOVYhdk1? MWPTRW5ITVJ?
no-10 NIXaSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLMN25yUUN3ME23MlI6KG6P M2jDVnNCVkeHUh?=
SK-NEP-1 NIHHdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M16xfWlEPTB;OD63PUBvVQ>? Mnj0V2FPT0WU
L-540 M{D0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\JSFJKSzVyPUGwMlQzKG6P NEHXN3pUSU6JRWK=
JiyoyeP-2003 NEPubVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLjNWY6UUN3ME2xNE46PCCwTR?= NF7rcphUSU6JRWK=
HH MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXrPIFOUUN3ME2xNU4{QSCwTR?= MVHTRW5ITVJ?
SR MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHKW|VKSzVyPUGxMlQ2KG6P MUfTRW5ITVJ?
QIMR-WIL NHjCcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C1U2lEPTB;MUGuPFUhdk1? MlfqV2FPT0WU
A4-Fuk NVe1fmcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXNOXJmUUN3ME2xN{4yOiCwTR?= NVvuTnBzW0GQR1XS
CESS NWXUWFBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7qOXkzUUN3ME2xN{4yOyCwTR?= Mm[2V2FPT0WU
KE-37 NUTLSotiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XONWlEPTB;MU[uNFchdk1? NWTQZoY4W0GQR1XS
SK-UT-1 NXjSblc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF4LkixJI5O MVHTRW5ITVJ?
SIG-M5 M1uzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Hid2lEPTB;MUeuNlUhdk1? M4DXdHNCVkeHUh?=
HT M4XNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPQc2U3UUN3ME2xO{43KG6P MV3TRW5ITVJ?
DEL M3GyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fHemlEPTB;MUeuPVkhdk1? NVLRWJlRW0GQR1XS
SK-PN-DW MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDpTWM2OD1{MD6yN{BvVQ>? Mk\vV2FPT0WU
RPMI-8402 M2DHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJzLke3JI5O NF2wd3FUSU6JRWK=
RPMI-6666 MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2qw[WlEPTB;MkSuOFIhdk1? MofZV2FPT0WU
NCI-H720 NEDCeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{C4[WlEPTB;MkWuOFEhdk1? M37sZnNCVkeHUh?=
EW-16 M{fnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJ4Lki3JI5O MXrTRW5ITVJ?
BL-70 Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPxTWM2OD1{OD6zPEBvVQ>? MVfTRW5ITVJ?
SF126 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmq5TWM2OD1|MD6zPEBvVQ>? NITteFVUSU6JRWK=
BC-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTKTWM2OD1|MT6yOkBvVQ>? NVnRWmQ1W0GQR1XS
MHH-PREB-1 M37XSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTN{LkS0JI5O NF\Bb5NUSU6JRWK=
A101D M2Xjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTN{Lk[yJI5O MmDUV2FPT0WU
NMC-G1 NX7LTFE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPnO2ZKSzVyPUOzMlY4KG6P M4HK[XNCVkeHUh?=
LB1047-RCC NGqy[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTN2Lk[5JI5O M1uzbnNCVkeHUh?=
EM-2 M4Pxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T6TGlEPTB;M{iuOVMhdk1? NWTzNo9vW0GQR1XS
COLO-684 NYGycWZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPS[INKSzVyPUO5Mlghdk1? NXy3cGJLW0GQR1XS
Becker NG\2WJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3UZm81UUN3ME20NU4xPSCwTR?= NIjmfItUSU6JRWK=
BL-41 MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33Ob2lEPTB;NEOuOlYhdk1? M2TySHNCVkeHUh?=
MDA-MB-134-VI Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzOTWM2OD12ND6wNkBvVQ>? NULKcWtWW0GQR1XS
L-363 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTR2LkezJI5O NGT1dXZUSU6JRWK=
ECC4 MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT0T4VKSzVyPUS0Mlc5KG6P NHjhV3hUSU6JRWK=
A388 NV7tdpZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf6TWM2OD12ND64NkBvVQ>? NXv3[IdxW0GQR1XS
HEL MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ntWmlEPTB;NEmuO|khdk1? MkH0V2FPT0WU
RKO NYK0SZQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC4RWFKSzVyPUWwMlI6KG6P M4X6NHNCVkeHUh?=
KINGS-1 NGPDVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NICxXlBKSzVyPUWxMlU2KG6P MljGV2FPT0WU
EB-3 NIjvcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvEeodCUUN3ME21Nk43PyCwTR?= MnrsV2FPT0WU
ARH-77 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDvT5cyUUN3ME21Nk45KG6P Mn3nV2FPT0WU
GCIY MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTV|LkS2JI5O MWfTRW5ITVJ?
NCI-H1304 M4fKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVv1S3RLUUN3ME21O{4zOiCwTR?= NVzqWIY6W0GQR1XS
KARPAS-299 NW\KblFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MniyTWM2OD14MT64NkBvVQ>? M2LLdHNCVkeHUh?=
IA-LM NGnQTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn2zTWM2OD14OD6xN{BvVQ>? Mn3LV2FPT0WU
GI-1 NXvzSYF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3STWM2OD15MD6zPUBvVQ>? MWrTRW5ITVJ?
TE-11 MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjvTWM2OD15Nz6xO{BvVQ>? NH;ITlFUSU6JRWK=
LS-411N M{HzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTd5LkW3JI5O M2jmOHNCVkeHUh?=
no-11 M{Tibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTh|LkK0JI5O Ml\OV2FPT0WU
MV-4-11 MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37tTGlEPTB;OEOuO|Mhdk1? NYC2[3RMW0GQR1XS
BV-173 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\3NGhuUUN3ME24N{46PyCwTR?= NILqSlBUSU6JRWK=
CMK NX7jSY91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXXUWFIUUN3ME24OE4yPiCwTR?= NEHQRlZUSU6JRWK=
LC4-1 NFflb4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHqzO3VKSzVyPUi2MlczKG6P M3jxV3NCVkeHUh?=
COR-L279 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTh5LkK1JI5O NEK5SHhUSU6JRWK=
NCI-H209 MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTh5LkSxJI5O M2Hne3NCVkeHUh?=
Raji MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjKb4JsUUN3ME24PU44OiCwTR?= NHjKbpBUSU6JRWK=
LB996-RCC Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3hTWM2OD17Mz60N{BvVQ>? NWnlS4s6W0GQR1XS
NCI-H526 M136SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITOUGlKSzVyPUmzMlU6KG6P M3nJR3NCVkeHUh?=
KGN MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTl4LkK5JI5O MVHTRW5ITVJ?
MOLT-4 MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTl4Lke5JI5O M4HuR3NCVkeHUh?=
PF-382 NUXEfplCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTl4Lke5JI5O M2G2Z3NCVkeHUh?=
BC-3 M1fETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInpcGZKSzVyPUm5MlE5KG6P NGC4bWZUSU6JRWK=
KARPAS-422 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;y[mlEPTB;MUCyMlA6KG6P NHj3bHFUSU6JRWK=
SBC-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj4fpJzUUN3ME2xNFcvPzVibl2= NH7xT4JUSU6JRWK=
LC-1F NXXoSZhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFyOD6wOUBvVQ>? M{CxT3NCVkeHUh?=
GB-1 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD6bYhLUUN3ME2xNFkvODJibl2= M4nxcHNCVkeHUh?=
SNB75 M3;zZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\TcmlEPTB;MUG5MlY6KG6P NHSxWHhUSU6JRWK=
BB65-RCC NVKzXG9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLmS3RwUUN3ME2xNVkvQTNibl2= MoPkV2FPT0WU
NCI-N87 M1nZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX2cHdHUUN3ME2xNlEvQThibl2= MmrXV2FPT0WU
IST-MEL1 M2\ZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF{Mj6zPEBvVQ>? M2nQeHNCVkeHUh?=
HOP-62 NWH5[VluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT3TWM2OD1zMk[uPFkhdk1? M4O1WnNCVkeHUh?=
ACN MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m0SWlEPTB;MUS2Mlc2KG6P NWj0WnI4W0GQR1XS
DMS-114 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjwW4NKSzVyPUG1NE43PyCwTR?= M1vx[HNCVkeHUh?=
MLMA NXy1WIJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XY[2lEPTB;MUW5Mlg5KG6P MXjTRW5ITVJ?
HT-144 NGjGVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jBTmlEPTB;MU[1MlQ{KG6P M{npVHNCVkeHUh?=
C2BBe1 MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PhOWlEPTB;MU[3Mlc3KG6P MmK4V2FPT0WU
L-428 NFrlW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfNd5VUUUN3ME2xO|cvPyCwTR?= M3LrbnNCVkeHUh?=
DU-4475 NFLIT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTITWM2OD1zOEeuOlghdk1? M2\z[nNCVkeHUh?=
CP67-MEL MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF7OT6zPEBvVQ>? M{fJenNCVkeHUh?=
MEG-01 MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDQTWM2OD1{MEGuPVYhdk1? MlTnV2FPT0WU
IST-SL2 NHWyUmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTJyOD62N{BvVQ>? MUXTRW5ITVJ?
ES8 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjxTplKSzVyPUKyOU46PCCwTR?= NFHqO|JUSU6JRWK=
COLO-800 NH;iPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXQeHRKSzVyPUKzOU4zQCCwTR?= NUiwe3dCW0GQR1XS
MFH-ino NYXobI5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\wfVZWUUN3ME2yN|UvQDRibl2= M1uwN3NCVkeHUh?=
OVCAR-4 NWn2dlBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCyTWM2OD1{M{euNlQhdk1? MkHMV2FPT0WU
PSN1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor4TWM2OD1{NEKuO|Ehdk1? MXfTRW5ITVJ?
EW-12 NV;pU|Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW0VJhKSzVyPUK0N{4yKG6P NHu1dYdUSU6JRWK=
HCC1599 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJ4MT60O{BvVQ>? NIK4PZlUSU6JRWK=
SJSA-1 M3rkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVyyXWtsUUN3ME2yO|EvPDZibl2= NVfDdI9NW0GQR1XS
ST486 M{Pnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni4TWM2OD1{OU[uNVQhdk1? NGTpOHNUSU6JRWK=
NOMO-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTNyMD6yNUBvVQ>? MkTCV2FPT0WU
MN-60 NVTTUIxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTNyNT6zNkBvVQ>? MmfRV2FPT0WU
HCC1187 NYrNb3JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTNyNz6yOUBvVQ>? NEPIe2ZUSU6JRWK=
SW982 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrnZm5KSzVyPUOxOE44PSCwTR?= NF\lZZdUSU6JRWK=
LB647-SCLC MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG2eodKSzVyPUOyPE44OSCwTR?= M1jYO3NCVkeHUh?=
HC-1 NXTLR3FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHCTWM2OD1|M{WuOUBvVQ>? M1\w[3NCVkeHUh?=
EHEB M3;3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPBcIFTUUN3ME2zN|cvPTJibl2= M13kWXNCVkeHUh?=
TUR NW\wfYZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2SwfWlEPTB;M{[zMlk2KG6P NH;3ZmxUSU6JRWK=
LU-139 M2O4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTN5OD6wNkBvVQ>? NYX5Uo5ZW0GQR1XS
NB1 NITiTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTN6ND60OUBvVQ>? MmGzV2FPT0WU
BB30-HNC M2nwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDXZYU5UUN3ME2zPFgvOzJibl2= M1LBXnNCVkeHUh?=
HAL-01 Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nZR2lEPTB;M{i5MlI3KG6P MofhV2FPT0WU
K5 MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr3Vmx3UUN3ME20NVEvOzdibl2= NYH3UJg2W0GQR1XS
MZ2-MEL NVPJV3o1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfD[I9lUUN3ME20NVMvPjRibl2= M1z0SnNCVkeHUh?=
RXF393 NUjFRVRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXPdHExUUN3ME20NVYvPDVibl2= NWjZbnJsW0GQR1XS
NCI-H1648 NEW3W2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X4ZWlEPTB;NEG3MlU{KG6P MnPPV2FPT0WU
TE-12 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTR|ND6yOkBvVQ>? NFv1cWdUSU6JRWK=
EoL-1- M1j0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke1TWM2OD12M{euPVghdk1? NWixZ3pEW0GQR1XS
JAR NIrM[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPQR3U{UUN3ME20N|gvPjJibl2= MYHTRW5ITVJ?
DSH1 NVLFWnllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTR3OD65NUBvVQ>? MW\TRW5ITVJ?
NCI-H187 NHXLb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fFeGlEPTB;NE[yMlgyKG6P NILsVXlUSU6JRWK=
HCE-4 NHHVRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTR5Nz62OkBvVQ>? NV[yN2h3W0GQR1XS
8-MG-BA MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2exV2lEPTB;NUixMlUzKG6P NF;XO3VUSU6JRWK=
KLE MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITRWI9KSzVyPUW4OU4zKG6P MWDTRW5ITVJ?
KNS-42 NELzZ|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTV6Nj64NUBvVQ>? MYTTRW5ITVJ?
MSTO-211H MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz3S5RKSzVyPU[wPU44PCCwTR?= M{ftTHNCVkeHUh?=
GDM-1 M{XpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\zfJBCUUN3ME22NVQvODlibl2= NYTF[4Y5W0GQR1XS
TE-1 MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHpOHVkUUN3ME22OFYvOTJibl2= M1rCcHNCVkeHUh?=
BT-474 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGO1bndKSzVyPU[0O{4xPiCwTR?= MkHHV2FPT0WU
KARPAS-45 M1y3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzLTWM2OD14NEeuOkBvVQ>? NWi3T|ZPW0GQR1XS
MOLT-16 M3vQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljlTWM2OD14NEeuPVMhdk1? M17UcXNCVkeHUh?=
KURAMOCHI MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjKOYJGUUN3ME22OVcvPTFibl2= NFvkNZlUSU6JRWK=
K-562 NU\DVmxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;GTWM2OD14NkmuOVEhdk1? M4i1THNCVkeHUh?=
EKVX MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PrWGlEPTB;NkeyMlcyKG6P M3HMcHNCVkeHUh?=
GAK NX;pXIZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnOxTWM2OD14N{WuN{BvVQ>? M1:zR3NCVkeHUh?=
NCI-SNU-5 MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fCVWlEPTB;NkmwMlAyKG6P M{fVdHNCVkeHUh?=
NCI-H2126 NEPJU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofQTWM2OD15Mk[uPFchdk1? NVLjNGFyW0GQR1XS
CTV-1 NWXXeZlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3JXHNKSzVyPUe0OE46KG6P NFfVNFRUSU6JRWK=
SW962 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEW5U5ZKSzVyPUe0PE41PCCwTR?= M{f4RXNCVkeHUh?=
MONO-MAC-6 NWLvbopyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLJeVJKSzVyPUe1Ok46OyCwTR?= NILwS|JUSU6JRWK=
NCI-H748 NVPyTm4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XRVmlEPTB;N{W4Mlk6KG6P NFq5T3VUSU6JRWK=
NCI-H524 NEexUZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTVTWM2OD15OECuO|Mhdk1? NYTsR5BQW0GQR1XS
LS-123 NV61R4VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvFc3pKSzVyPUe5OU43QSCwTR?= M2OzOXNCVkeHUh?=
NB7 Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPjN4hKSzVyPUixOE4yPCCwTR?= MXjTRW5ITVJ?
LS-1034 NFvhbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHLbVNVUUN3ME24NlgvQThibl2= MoO5V2FPT0WU
TE-5 M2K5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFr3ZYdKSzVyPUi4N{42PiCwTR?= MoPQV2FPT0WU
A704 NHPXe21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTh7OT6xOUBvVQ>? NHHTU|hUSU6JRWK=
TK10 NInrTppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTlzNj6wN{BvVQ>? NIC2VYlUSU6JRWK=
NCI-H345 NX;rR5lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnLTWM2OD17NEOuNlIhdk1? Mn3IV2FPT0WU
CGTH-W-1 M4PNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\uNYhKSzVyPUm0PE4yOyCwTR?= NYrrWWVPW0GQR1XS
NCI-H510A M2e5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDmfG1KSzVyPUm4OU4yOiCwTR?= MXzTRW5ITVJ?
NCI-H1963 MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnhb|JIUUN3ME2xMlA{Ojl{IN88US=> MVvTRW5ITVJ?
SCC-3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;pNlZKSzVyPUGuNFM1OTRizszN NH7UTpVUSU6JRWK=
EW-11 NXXIRYRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFwMEi3OFMh|ryP M4LJb3NCVkeHUh?=
CPC-N NY[1bHFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:3R5lKSzVyPUGuNFg5KM7:TR?= NWXHOXhSW0GQR1XS
NCI-H1417 Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXQN5lKSzVyPUGuNVIzPiEQvF2= NYrqO2ppW0GQR1XS
DG-75 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\M[|lKSzVyPUGuNVYzQDVizszN MYLTRW5ITVJ?
HD-MY-Z NWD3SGFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC2[5VKSzVyPUGuNVY1OTZizszN MYnTRW5ITVJ?
ATN-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHyyeJBKSzVyPUGuNlYzODlizszN MYnTRW5ITVJ?
KM-H2 NFHYTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Lh[WlEPTB;MT6yOlQxQCEQvF2= NH:yPIJUSU6JRWK=
NCI-H2081 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;MTWM2OD1zLkK2OlM4KM7:TR?= NWCxVG9YW0GQR1XS
HL-60 M3PweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzkUVhTUUN3ME2xMlI3QTV7IN88US=> M1nab3NCVkeHUh?=
DB MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwMkeyOFIh|ryP NXvkWIZoW0GQR1XS
NCI-H1522 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;ib2hKSzVyPUGuNlg5QDdizszN M3:zTXNCVkeHUh?=
AM-38 MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvYTWM2OD1zLkOwO|Ih|ryP NV\rRYZnW0GQR1XS
NCI-H446 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7DZ4FiUUN3ME2xMlMzOTJzIN88US=> MnTjV2FPT0WU
SU-DHL-1 NWDETIdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTFwM{K4NFEh|ryP MVvTRW5ITVJ?
NH-12 NFHFdGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HibWlEPTB;MT6zOlM4PCEQvF2= M3S5WnNCVkeHUh?=
DMS-79 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzvTWM2OD1zLkO2PFY3KM7:TR?= MVnTRW5ITVJ?
NCI-H716 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv3dWVKSzVyPUGuN|g6QDZizszN M{nmSXNCVkeHUh?=
ML-2 MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmroTWM2OD1zLkSxOVI6KM7:TR?= M2DJXnNCVkeHUh?=
NB10 MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rjXWlEPTB;MT60OlY{OiEQvF2= MmmwV2FPT0WU
ONS-76 NWLRXnBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTFwNUO1Olkh|ryP MWPTRW5ITVJ?
LOUCY MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C2R2lEPTB;MT61OFY2PyEQvF2= NInYUmJUSU6JRWK=
SCLC-21H MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwNUi1PFIh|ryP NFXwT5RUSU6JRWK=
TGW M{LTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPZS2tKSzVyPUGuOlM6PzVizszN NX[4fWQ6W0GQR1XS
LXF-289 M3LiSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwN{OyOlgh|ryP MYjTRW5ITVJ?
BB49-HNC NUW3fWlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2WxUmlEPTB;MT63N|U5PiEQvF2= MXrTRW5ITVJ?
NCI-H747 NHi2TYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX2TWM2OD1zLke1N|Q3KM7:TR?= NGTqS25USU6JRWK=
LU-165 M{TS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlK2TWM2OD1zLki0PVg3KM7:TR?= NW[xSolJW0GQR1XS
OMC-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFwOUWwOlYh|ryP NWrTUpczW0GQR1XS
RCC10RGB MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;2dGptUUN3ME2xMlk2QDF5IN88US=> NF30dIVUSU6JRWK=
SW684 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrQTWM2OD1zLkm2NFk6KM7:TR?= MVLTRW5ITVJ?
TE-8 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mon2TWM2OD1{LkC1OVU6KM7:TR?= NWTCdotCW0GQR1XS
SK-N-DZ MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrCZ5hKSzVyPUKuNVMzPzRizszN MUjTRW5ITVJ?
EVSA-T NUDUfYg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fCRmlEPTB;Mj6xO|MyPSEQvF2= NFr4e4lUSU6JRWK=
KASUMI-1 M1TS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zLfWlEPTB;Mj6xPFgyPSEQvF2= MYHTRW5ITVJ?
NKM-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHjSJhKSzVyPUKuNlU1PzJizszN MnjoV2FPT0WU
CAL-148 M3jOWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH3dJdKSzVyPUKuN|M3OTRizszN MkDJV2FPT0WU
NCI-H64 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\rXJpzUUN3ME2yMlM1OjN{IN88US=> M4jnZ3NCVkeHUh?=
KNS-81-FD MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mke5TWM2OD1{LkO2OlIh|ryP MlziV2FPT0WU
KM12 NHf4OW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2qzZmlEPTB;Mj60NFg{QSEQvF2= NWK4WWl1W0GQR1XS
SW954 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJwNEe3O|kh|ryP MnTWV2FPT0WU
NCI-H1395 NUXSZXdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJwNUK2OFUh|ryP MmTQV2FPT0WU
DJM-1 NGTjUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJwNkC2N{DPxE1? MYjTRW5ITVJ?
COLO-668 Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonRTWM2OD1{LkiyOlk2KM7:TR?= M4rtU3NCVkeHUh?=
NCI-H1436 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJwOEW2NVUh|ryP NFHlPYlUSU6JRWK=
LB2241-RCC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW0NVR{UUN3ME2yMlg3QDN7IN88US=> M2TlfXNCVkeHUh?=
GT3TKB NXjlSI5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjtc5dYUUN3ME2yMlg6ODV3IN88US=> M4e1cnNCVkeHUh?=
COLO-824 NUDheFlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nDSWlEPTB;Mj64PVc3QCEQvF2= NI\ieZlUSU6JRWK=
ES1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\DVYlKSzVyPUKuPFk5PzlizszN NGr1bVRUSU6JRWK=
LB771-HNC NUjEfZdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTjRmh6UUN3ME2yMlkxQTR4IN88US=> NFHI[nZUSU6JRWK=
GI-ME-N M1PacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHeybW1KSzVyPUOuNFA6ODRizszN Mn;VV2FPT0WU
NALM-6 MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTNwMEC5N|Mh|ryP MWXTRW5ITVJ?
LU-134-A MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni2TWM2OD1|LkC1OFI2KM7:TR?= NGPqPINUSU6JRWK=
DMS-153 Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;DfmlEPTB;Mz6wOVgzPCEQvF2= NHG5R5dUSU6JRWK=
MZ1-PC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPvTWM2OD1|LkC5NFc5KM7:TR?= NWewb2pCW0GQR1XS
NCI-H1155 MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTNwMUG2NUDPxE1? MWHTRW5ITVJ?
CAS-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnITWM2OD1|LkGzO|A4KM7:TR?= NXWxNG1bW0GQR1XS
D-502MG M36ycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljsTWM2OD1|LkG0N|kh|ryP MXjTRW5ITVJ?
NCI-H2141 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTNwMUe0OVIh|ryP MoPXV2FPT0WU
NB6 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTZcJVEUUN3ME2zMlE5OjV7IN88US=> NIHVRVJUSU6JRWK=
NCCIT NFPMV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXH[oRKSzVyPUOuNlE5ODlizszN NU[0PYROW0GQR1XS
NB69 NUfyO5NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTNwM{G4PVEh|ryP NV\OZmI4W0GQR1XS
JVM-2 NWHSRVVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGL6bZZKSzVyPUOuN|Y1OzNizszN MXnTRW5ITVJ?
K052 NIK2bXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\xVmlEPTB;Mz6zO|k3QCEQvF2= M4D4[HNCVkeHUh?=
HCC2157 NWPlcJBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\vTWM2OD1|LkWzNlI5KM7:TR?= MYHTRW5ITVJ?
KMOE-2 M13qVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:5TWM2OD1|LkW0NlQzKM7:TR?= NHThd5pUSU6JRWK=
SF268 MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHtdnFKSzVyPUOuO|E2PTRizszN MV\TRW5ITVJ?
CHP-126 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTNwN{[0OVgh|ryP M2fyNHNCVkeHUh?=
CP66-MEL NFm1NYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvIdYdKSzVyPUOuO|kxQTRizszN NV3kfJp5W0GQR1XS
NCI-H69 NVXDe4ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF25NWVKSzVyPUSuNFE6OzZizszN NUD1fmhVW0GQR1XS
A253 NYKwOnJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUexRmtJUUN3ME20MlAzOTBzIN88US=> MorjV2FPT0WU
NB14 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{mxfmlEPTB;ND6xNFQ4QSEQvF2= MmXjV2FPT0WU
NCI-H1694 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPL[HRKSzVyPUSuNVMyOTJizszN Mkm2V2FPT0WU
NCI-H2196 MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHITWM2OD12LkG3NVY6KM7:TR?= NXLFR|VMW0GQR1XS
TE-9 NIjwcmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPNTWJKSzVyPUSuNVc2QDJizszN MlTlV2FPT0WU
D-283MED NGfLWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTRwMUi4OEDPxE1? MVHTRW5ITVJ?
OCI-AML2 NYjJT3d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInjOXZKSzVyPUSuNVk1QDlizszN MoXxV2FPT0WU
D-263MG NFntXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrLTpJWUUN3ME20MlIzQTZzIN88US=> MVnTRW5ITVJ?
MPP-89 MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DkVWlEPTB;ND6yO|MxPCEQvF2= MYPTRW5ITVJ?
LAMA-84 MorRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjLTVB7UUN3ME20MlMxPDJzIN88US=> NFjzd5pUSU6JRWK=
LB373-MEL-D NHPmS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTRwM{[3PFkh|ryP M3LXXnNCVkeHUh?=
UACC-257 MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvuTWM2OD12LkO5OVM1KM7:TR?= MUXTRW5ITVJ?
MC-CAR MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTjTWM2OD12LkSzPVkh|ryP MYrTRW5ITVJ?
COLO-320-HSR NH\iTXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXZTWM2OD12LkS0OFI4KM7:TR?= MXfTRW5ITVJ?
P30-OHK NX7mc2NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTRwNk[1PFEh|ryP NFXDW4ZUSU6JRWK=
UACC-812 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn3fYVKSzVyPUSuOlkyPjFizszN NH3XcHZUSU6JRWK=
CTB-1 Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[2e2lEPTB;ND63NVU2PSEQvF2= M1vNfXNCVkeHUh?=
ALL-PO M4\wcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\oWGhKSzVyPUSuPFQxPzdizszN NEHhUmhUSU6JRWK=
SK-MEL-2 Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTRwOE[5OVUh|ryP NIGxOpdUSU6JRWK=
TC-YIK Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrCeolKSzVyPUSuPVc6PDJizszN MV3TRW5ITVJ?
NCI-H1882 M3HNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPGWYVKSzVyPUWuNFIxODFizszN MnjOV2FPT0WU
MHH-CALL-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3GzOGlEPTB;NT6wOVA1OiEQvF2= M{OySXNCVkeHUh?=
U-87-MG M3PqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[3fJVKSzVyPUWuNFk1PjZizszN NGCzTIxUSU6JRWK=
NCI-H1092 M13KcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHDN3RoUUN3ME21MlI3PTV3IN88US=> NWC2RpNwW0GQR1XS
TE-441-T NGL0OpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j0W2lEPTB;NT6yO|gzKM7:TR?= MW\TRW5ITVJ?
SK-MEL-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFOwPWtKSzVyPUWuNlkxPDRizszN MorHV2FPT0WU
EW-22 NGnrbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjPTWM2OD13LkK5OFY3KM7:TR?= MVrTRW5ITVJ?
MZ7-mel MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3ReGhKSzVyPUWuOFA3QTFizszN MYHTRW5ITVJ?
LP-1 MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\vOmFFUUN3ME21MlQyOjlzIN88US=> NEXGW5JUSU6JRWK=
NCI-SNU-16 NX3wPIdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDQbYhKSzVyPUWuOlQxPzRizszN NFjIeHdUSU6JRWK=
LU-65 NVrLS|JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjmZnhWUUN3ME21Mlc3Ozd|IN88US=> MVzTRW5ITVJ?
CW-2 NF\Ud21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm1cJNKSzVyPUWuPFU6PTlizszN MV;TRW5ITVJ?
WSU-NHL MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD4SllKSzVyPUWuPVUyPzRizszN MoDkV2FPT0WU
IST-MES1 NFTpN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW3TWM2OD13Lkm1OFQ{KM7:TR?= MVXTRW5ITVJ?
U-266 NIjkfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL4R2hjUUN3ME21Mlk5OjB{IN88US=> Mlf0V2FPT0WU
TALL-1 Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfGTWM2OD14LkG0Olg5KM7:TR?= NGrac|RUSU6JRWK=
Calu-6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PM[2lEPTB;Nj6xOVMyPiEQvF2= NY[zRVJrW0GQR1XS
MMAC-SF MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TmRmlEPTB;Nj6xPFU2PiEQvF2= NUHtNnY5W0GQR1XS
NCI-H82 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjtRVJwUUN3ME22MlIxPDh7IN88US=> NF7EV|NUSU6JRWK=
RS4-11 NEDFRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\BcppKSzVyPU[uNlU5QTdizszN NUfVZ21vW0GQR1XS
SNU-C2B NFHXfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlf6TWM2OD14LkSwPVY6KM7:TR?= NVz3fJFmW0GQR1XS
BOKU NHvJSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7XTWM2OD14LkS3OVk4KM7:TR?= M{myb3NCVkeHUh?=
C8166 MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2faZmlEPTB;Nj61OVkyOiEQvF2= MVTTRW5ITVJ?
D-247MG MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTdwMESzOFch|ryP NVnRN2xrW0GQR1XS
EW-18 NILGVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7ETWM2OD15LkC3NlkzKM7:TR?= MnmxV2FPT0WU
KG-1 MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HLN2lEPTB;Nz62Nlc{QCEQvF2= NV\JUI15W0GQR1XS
REH MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTdwNkixNFkh|ryP NFXDXJlUSU6JRWK=
U-698-M MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTdwOESzNVUh|ryP NGDVZYtUSU6JRWK=
KP-N-RT-BM-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTdwOUOwNlkh|ryP M3W2e3NCVkeHUh?=
MS-1 NG\vc2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvkO2E1UUN3ME23Mlk3ODRzIN88US=> MYTTRW5ITVJ?
SNU-C1 M1XuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TBbGlEPTB;Nz65PFE6OiEQvF2= M1rURnNCVkeHUh?=
SK-MM-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PmcmlEPTB;OD6yOlA3PSEQvF2= Mn;EV2FPT0WU
LAN-6 MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRThwM{CwNFEh|ryP MnjXV2FPT0WU
NEC8 M{\L[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XKfmlEPTB;OD6zNFY6OSEQvF2= MoH6V2FPT0WU
NCI-H1770 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLSW5pKSzVyPUiuN|gxODJizszN MYfTRW5ITVJ?
D-336MG MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PhTmlEPTB;OD60NFEyPiEQvF2= NFHCTpBUSU6JRWK=
COLO-829 NYXKZnNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\QTWM2OD16LkS4PFc6KM7:TR?= M3X5UnNCVkeHUh?=
LS-513 NXjK[FZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRThwNUm1PVkh|ryP NW\XSG41W0GQR1XS
YT MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRThwNkK0Nlch|ryP NFn0[2JUSU6JRWK=
EW-24 NYX6V5NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X5R2lEPTB;OD63OlU1KM7:TR?= MkHwV2FPT0WU
IST-SL1 NGXYVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nVVWlEPTB;OD64OlU1OyEQvF2= M4PCZnNCVkeHUh?=
CA46 MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\RTVlKSzVyPUiuPVUxQThizszN Ml34V2FPT0WU
NCI-H1838 M3\3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\oTWM2OD16Lkm4OlAzKM7:TR?= MmHIV2FPT0WU
NCI-H719 Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXmTWM2OD17LkK1Nlc6KM7:TR?= NHvMfWdUSU6JRWK=
HCE-T NIri[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTlwM{C4OVEh|ryP NIq2UG5USU6JRWK=
A498 MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK4TWM2OD17LkO2NVI1KM7:TR?= MlO3V2FPT0WU
LB831-BLC M2O3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX3[XNKSzVyPUmuO|Y2OjFizszN MljhV2FPT0WU
SKM-1 Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTlwOEW5OlMh|ryP NXPY[m55W0GQR1XS
THP-1 NIfzWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF21U29KSzVyPUmuPVY6OThizszN MVnTRW5ITVJ?
SHP-77 NGnTVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\Ub2lEPTB;MUCuOFA4KM7:TR?= MV;TRW5ITVJ?
EW-3 NYr4[FFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFy1Zm1KSzVyPUGwMlYzQDlizszN MnjvV2FPT0WU
KY821 NWrRZ2o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn6TWM2OD1zMD63OlMh|ryP NIfONGpUSU6JRWK=
NCI-SNU-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXuTWM2OD1zMT6wNlE4KM7:TR?= NV60RnpvW0GQR1XS
HCC2218 M4TqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCwTWM2OD1zMT6zPVg3KM7:TR?= NV3pPGhHW0GQR1XS
IM-9 NG[xTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3GTWM2OD1zMT61NVA3KM7:TR?= M4\mdnNCVkeHUh?=
NCI-H889 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFzLkWzNVMh|ryP MYHTRW5ITVJ?
HDLM-2 NUjBdZNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\WfmlEPTB;MUKuOFE2QSEQvF2= NHLGR29USU6JRWK=
LB2518-MEL NXnNepF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF{Lk[4NVUh|ryP NXX4TnQ2W0GQR1XS
NCI-H23 MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnO5TWM2OD1zMz6yOFI2KM7:TR?= MmDXV2FPT0WU
NB17 Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zhXGlEPTB;MUOuOFU4QSEQvF2= NUHM[lNTW0GQR1XS
NCI-H322M NVXtXm1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF2LkSwOlgh|ryP NEPtZphUSU6JRWK=
SUP-T1 NXrZWJB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP4WYdKSzVyPUG0MlQyOyEQvF2= MnXoV2FPT0WU
ES3 NV\rXXQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF3LkC3NFMh|ryP MonsV2FPT0WU
ES5 NYm3emxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS0TWM2OD1zNT6wO|g4KM7:TR?= NXXJPHlQW0GQR1XS
NCI-H1650 NWOwfIEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTYWI01UUN3ME2xOU41QTd7IN88US=> M3yxdXNCVkeHUh?=
NCI-H226 MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[4dWlEPTB;MUWuPFc3QCEQvF2= NFvtbVFUSU6JRWK=
COR-L88 M1zC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\adG9KSzVyPUG2MlMyPCEQvF2= NV\Ne2Z3W0GQR1XS
SCC-15 MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF4LkO4Olkh|ryP MV;TRW5ITVJ?
GOTO NVvKUWpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF4LkS3PVMh|ryP NHXVc3BUSU6JRWK=
SIMA M{fWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjpV3JQUUN3ME2xOk41QDB{IN88US=> MUTTRW5ITVJ?
NCI-H1299 NVHTUXpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPHTVdKSzVyPUG3MlE2QTFizszN M2XsOHNCVkeHUh?=
NCI-H1581 MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;zWYRKSzVyPUG3MlQzOTlizszN NUHlV2xYW0GQR1XS
MHH-NB-11 MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF5Lkm2PFMh|ryP NUTwR3lRW0GQR1XS
MFM-223 M2LwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG5cZVKSzVyPUG4MlA2OzhizszN NYnJcJZbW0GQR1XS
ES7 NEG2bHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLxTWM2OD1zOD61OFMyKM7:TR?= MVfTRW5ITVJ?
JVM-3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33TNGlEPTB;MUiuO|E4KM7:TR?= NGLOV5ZUSU6JRWK=
RL M1nuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NISxeYVKSzVyPUKwMlM5QCEQvF2= MoTaV2FPT0WU
EC-GI-10 NVe0Rnd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJzLkKwOFEh|ryP NFzseGxUSU6JRWK=
LNCaP-Clone-FGC NFrhbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zU[GlEPTB;MkGuOlc3QCEQvF2= NH3QOFhUSU6JRWK=
IMR-5 NYX6cGZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV24RYVSUUN3ME2yNU45PDl2IN88US=> NIrQUZBUSU6JRWK=
KP-N-YS NX3RTYNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTsTWM2OD1{MT64O|Uh|ryP NYTl[HdJW0GQR1XS
Mo-T M1XiRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjCcm5KSzVyPUKyMlIyQDVizszN MmPhV2FPT0WU
NCI-H128 NUHuOYc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7wTWM2OD1{Mz61PFU{KM7:TR?= NFPDRWZUSU6JRWK=
RH-1 M{P6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:yTmlEPTB;MkOuO|g3PiEQvF2= NEXnTFNUSU6JRWK=
NCI-H2171 NXPBfGVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJ2LkK0PFUh|ryP NHvTS|FUSU6JRWK=
RPMI-8866 NGnXepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rrfWlEPTB;Mk[uO|QzKM7:TR?= NVe5XGJxW0GQR1XS
SK-N-FI MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLPbGxqUUN3ME2yO{4{QDFzIN88US=> MXHTRW5ITVJ?
LOXIMVI M3zLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nkcmlEPTB;MkeuPFA2OSEQvF2= MWDTRW5ITVJ?
P31-FUJ Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjTdGNVUUN3ME2zNU42Ozd2IN88US=> MkjsV2FPT0WU
KMS-12-PE MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXhdGhXUUN3ME20PU42OzB{IN88US=> MUHTRW5ITVJ?

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-mTOR(S2448)/mTOR; 

PubMed: 23991038     


MCF-7-vector and MCF-7-ZNF703 cells were treated with DMSO, 0.1 µM rapamycin, or 1 µM rapamycin for 24 hours before cell lysis. Western blot analysis of lysates using the indicated antibodies. A GAPDH antibody was used as a loading control.

23991038
Growth inhibition assay
Cell proliferation; 

PubMed: 30393233     


(A) Effect of Rapamycin treatment on SK-N-SH cell proliferation. (B) Effect of Rapamycin treatment on SH-SY5Y cell proliferation. Rapamycin, except treatment of 10 µM for 12 h, can obviously inhibited proliferation of NB cells compared with corresponding control group (P<0.05). (*) indicates statistically significant difference with P<0.05.

30393233
Histomorphology
Haematoxylin & Eosin; 

PubMed: 28418837     


Representative pictures of H&E-stained U87MG cells. The fusiform cell body observed in control cells A. disappears in cells exposed to increasing doses of rapamycin for 24 h B.-E. Rapamycin produces a dose-dependent increase in the diameter of the cell body which develops a pyramidal shape. 1 nM (B); 10 nM (C); 100 nM (D); 1 μM (E) of rapamycin exposure.

28418837
Immunofluorescence
NeuN; 

PubMed: 28418837     


Immune-fluorescence of U87MG cells treated with vehicle A.-D. and rapamycin at the dose of 10 nM E.-H.; 100 nM I.-L.; 1 μM M.-P. In the first line cells were stained for the late post-mitotic neuronal marker NeuN. In the second line cells were stained for the nuclear dye DAPI. In the third line the merging between NeuN (green) and DAPI (blue) fluorescence is shown. In the fourth line a high magnification of the squared insert of line three is shown.

p62/Beclin; 

PubMed: 28819214     


(C,D) Rapamycin treatment reduced the aggregate level of p62 and Beclin 1 in cardiomyocytes. NRVCs were transduced with Ad-Nef or Ad-null for 48 hours and cells were fixed with 4% PFA. Fixed cells were stained with p62 and Beclin 1 antibody. 

28418837 28819214
ELISA
Type III collagen/Fibronectin; 

PubMed: 23364979     


(A) Rapamycin inhibits TGF-β1-induced type III collagen level in the culture medium of human lung fibroblast, evidenced by ELISA. Type III collagen level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. No significant difference was found between different concentration groups of rapamycin. (B) Rapamycin inhibits TGF-β1-induced fibronectin level in the culture medium of human lung fibroblast, shown by ELISA. Fibronectin level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. Values are mean of three independent experiments. No significant difference was found between different concentration groups of rapamycin. *p<0.05 vs. control; †p<0.05 vs. TGF-β1 group. TGF-β1, transforming growth factor β1.

23364979
In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]
- Collapse

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]
- Collapse
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]
- Collapse
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13
CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989，NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03433183 Recruiting Drug: Selumetinib|Drug: Sirolimus Malignant Peripheral Nerve Sheath Tumors|Neurofibromatosis 1 Sarcoma Alliance for Research through Collaboration|United States Department of Defense|AstraZeneca October 2 2019 Phase 2
NCT03933904 Recruiting Drug: Sirolimus Castleman Disease|Castleman''s Disease Multicentric University of Pennsylvania September 25 2019 Phase 2
NCT03972592 Recruiting Drug: Topical 0.1% Sirolimus|Drug: Topical Vehicle Vascular Malformations|Lymphatic Malformation University Hospital Tours|University Hospital Angers June 5 2019 Phase 2
NCT03811717 Completed Other: FAST+EX|Other: FAST Skeletal Muscle Energetics Queen''s University|University of Waterloo January 14 2019 Not Applicable
NCT03765944 Completed Drug: sirolimus Bioequivalence Study Nobelpharma December 5 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

  • Pan mTOR inhibitor

    KU-0063794 : mTORC1 and mTORC2, IC50=~10 nM.

  • FDA-approved mTOR Inhibitor

    Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).

  • Newest mTOR Inhibitor

    XL388 New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

  • Classic mTOR Inhibitor

    BEZ235 (NVP-BEZ235, Dactolisib) : Dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively.

Related mTOR Products

  • MHY1485 New

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021) New

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.

  • Dorsomorphin (Compound C) New

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

  • AZD8055

    AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.

  • Sapanisertib (INK 128, MLN0128,TAK-228)

    Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.

  • Tacrolimus (FK506)

    Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.

  • KU-0063794

    KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID